Seung Hwan Son

Prof. Seung Hwan Son


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 August 2026 in Organic Letters
Verified
Journal Article
Closed access
DRDeelip S. Rekunge
Deelip S. Rekunge
KOKyungsoo Oh
Kyungsoo Oh
CCChaeyeon Cho
Chaeyeon Cho
HYHeejung Yang
Heejung Yang
SSSeung Hwan Son
Seung Hwan Son
SKSeok-Ho KIM
Seok-Ho KIM

16 September 2026 in Molecules
Verified
Journal Article
Open access
PDF file
BNBui Hoang Huu Nhan
Bui Hoang Huu Nhan
SJSeong Ho Jeon
Seong Ho Jeon
SLSUJIN LEE
SUJIN LEE
SSSeung Hwan Son
Seung Hwan Son
YYYoung Duk Yang
Young Duk Yang
SKSeok-Ho KIM
Seok-Ho KIM
GPR119 is a promising target for the treatment of type 2 diabetes mellitus. Stimulating this receptor leads to the induction of glucose-dependent insulinotropic peptide and glucagon-like peptide 1, which improves systemic glucose homeostasis. Encouraged by our previous research, we replaced 5-nitropyrimidine with 1,3,5-triazine to reduce hepatotoxicity. A new series of compounds with a 1,3,5-triazine scaffold was synthesized and evaluated for their agonistic activities against human GPR119. Thirty-three compounds were synthesized and evaluated for their potential GPR119 agonist activities. Analogs with a 4-cyano and a 4-methylsulfonyl group in the aryl ring exhibited more potent activation than those analogs with a 4-trifluoromethyl group. Compound 3c had the most favorable EC50 value (hEC50 = 2.39 µM) and significantly induced glucagon-like peptide-1 secretion. Furthermore, docking simulations showed that compound 3c stably binds to the active site of GPR119.